Search
經導管主動脈瓣置換術之發展評析
經導管主動脈瓣置換術 (Transcatheter Aortic Valve Replacement，TAVR) 是一種近幾年來急速成長的心血管微創手術，用於治療主動脈瓣嚴重狹窄的病患。在過去，治療主動脈瓣狹窄多是透過開刀將人工瓣膜植入體內(Surgical Aortic Valve Replacement，SAVR)，在2011 年，Edwards Lifesciences 公司發表了全球第一個透過導管置放人工瓣膜的產品 － SAPIEN，臨床數據表現亮眼，引發TAVR的潮流，短短五年內，市場規模成長達十億美元，目前仍持續成長，預估在 2020 年達 14 億美元。
#經導管主動脈瓣置換術 #微創手術
呂克行（Kao H. Lu）╱RLM&K法律事務所美國專利律師
提出美國專利申請案時，如果申請人沒有向USPTO列出與該發明的先前相關申請案，會影響優先權日及賠償的結果，也會導致失去索賠申請的優先權日。在Medtronic CoreValve, LLC v. Edwards Lifesciences Corp.的案子中，聯邦上訴法院結論認爲Medtronic失去索賠優先權日是因爲專利擁有者本身並沒有列出兩個之前的優先申請案，不符合35 U.S.C. § 120.的規定......
Many MNCs invest in Singapore because of our skilled and hardworking workforce.
Edwards Lifesciences started producing heart valves using cow tissue in Singapore in 2005. It recruited older workers with sewing experience, mostly women, and trained them to stitch the heart valves. The same basic skills – sewing and stitching – but what a difference in the value of the job, the standards demanded, and the rewards to the workers. Here is one telling her story. – LHL
(Video courtesy of EDB)
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Our company is driven by a passion to help patients by ... ... <看更多>
edwards lifesciences 在 Edwards Lifesciences - Home | Facebook 的推薦與評價
Edwards Lifesciences is a global leader of patient-focused innovations for structural heart disease... One Edwards Way, Irvine, CA 92614. ... <看更多>